Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Ovid Therapeutics revenue
Ovid Therapeutics's revenue is $566,000.
What is Ovid Therapeutics's revenue?
- Ovid Therapeutics's revenue growth from 2020 to 2024 is -95.51%.
- Ovid Therapeutics has 67 employees, and the revenue per employee ratio is $8,447.
- Ovid Therapeutics's peak quarterly revenue was $208.4M in 2021(q1).
- Ovid Therapeutics peak revenue was $208.4M in 2021.
- Ovid Therapeutics annual revenue for 2023 was 392.0K, -73.91% growth from 2022.
- Ovid Therapeutics annual revenue for 2024 was 566.0K, 44.39% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Ovid Therapeutics historical revenue
Ovid Therapeutics's peak revenue was $208.4M in 2021. The peak quarterly revenue was $208.4M in 2021(q1).
Ovid Therapeutics's revenue increased from $12.6m in 2020 to $566.0K currently. That's a -95.51% change in annual revenue.
Ovid Therapeutics annual revenue
Ovid Therapeutics annual revenue over time
| Fiscal year / year | Ovid Therapeutics revenue |
|---|---|
| 2020 | $12.6M |
| 2021 | $208.4M |
| 2022 | $1.5M |
| 2023 | $392,000 |
| 2024 | $566,000 |
Rate Ovid Therapeutics' financial transparency
Ovid Therapeutics annual growth
Ovid Therapeutics saw the greatest revenue growth in 2021, when revenue increased by 1,551.57%.
Ovid Therapeutics had the lowest revenue growth in 2022, when revenue changed by -99.28%.
Ovid Therapeutics annual growth rate over time
| Year | Ovid Therapeutics growth |
|---|---|
| 2021 | 1552%↑ |
| 2022 | -99%↓ |
| 2023 | -74%↓ |
| 2024 | 44%↑ |
Ovid Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Ovid Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2020 | - | - | $6.9M | $5.7M |
| 2021 | $208.4M | - | - | - |
| 2022 | $1.4M | - | $11,102 | $46,280 |
| 2023 | $66,000 | $75,000 | $109,000 | $142,000 |
| 2024 | $148,000 | $169,000 | $173,000 | $76,000 |
Ovid Therapeutics jobs nearby
Do you work at Ovid Therapeutics?
Did Ovid Therapeutics meet its revenue projections?
Ovid Therapeutics financial information
| CEO | Jeremy Max Levin |
| Company Type | Public |
| Employees Number | 67 |
| Date Founded | 2014 |
| Headquarters | New York, New York |
| Number of Locations | 2 |
| Revenue | $566,000 |
| Net Income | -$54,169,029 |
| Tax Rate | -0.1% |
| Total Assets | $155,265,814 |
| Ticker | OVID |
Ovid Therapeutics jobs you might like
Ovid Therapeutics financing
Ovid Therapeutics received early financing of $5.1M on 2015-03-16.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $5M | 03/2015 |
| Series B | $75M | 08/2015 |
| Series C | $25.9M | 01/2017 |
| Post Ipo Equity | $28.2M | 02/2019 |
Ovid Therapeutics investors
| Investors | Security type |
|---|---|
| Jennison Associates | Series B |
| Redmile Group | Series B |
| Tekla Capital Management | Series B |
| DoubleLine Equity Healthcare Fund | Series B |
| Sphera Fund | Series B |
| Cormorant Asset Management | Series B |
| Sanofi Ventures | Series B |
| FMR Co. | Series B |
Ovid Therapeutics competitors
Ovid Therapeutics's top competitor, Catalyst Pharmaceuticals, earned an annual revenue of $491.7M.
Ovid Therapeutics's smallest competitor is Onspira Therapeutics with revenue of $410.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Zafgen | - | $6.5M | 20 | - |
| Kiniksa Pharmaceuticals | - | $423.2M | 111 | - |
| Axsome Therapeutics | - | $385.7M | 29 | - |
| Catalyst Pharmaceuticals | - | $491.7M | 51 | - |
| Retrophin | - | $198.3M | 262 | - |
| Aurinia Pharmaceuticals | - | $235.1M | 33 | - |
| Mustang Bio | - | $2.4M | 38 | - |
| Aldeyra Therapeutics | - | $1.0M | 19 | - |
| G1 Therapeutics | - | $82.5M | 148 | - |
| Onspira Therapeutics | - | $410,000 | 30 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Ovid Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Ovid Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Ovid Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Ovid Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Ovid Therapeutics. The data presented on this page does not represent the view of Ovid Therapeutics and its employees or that of Zippia.
Ovid Therapeutics may also be known as or be related to OVID THERAPEUTICS INC., Ovid Therapeutics, Ovid Therapeutics Inc, Ovid Therapeutics Inc. and Ovid Therapeutics, Inc.